Metastatic Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2030

Albany, NY -- (SBWire) -- 02/14/2020 --Metastatic Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Metastatic Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Pancreatic cancer is the fourth-leading cause of cancer death in both men and women, with an estimated 43,090 deaths in 2017 as per the American Cancer Society.
2. Pancreatic cancer is the 11th most common cancer in the United Kingdom, accounting for three per cent of all new cancer cases.
3. There were approximately 53,000 individuals diagnosed with cancer of the pancreas in the United States each year, and approximately 43,000 individuals succumb to the disease annually.

Key benefits of the report
1. Metastatic Pancreatic Cancer market report covers a descriptive overview and comprehensive insight of the Metastatic Pancreatic Cancer epidemiology and Metastatic Pancreatic Cancer market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Metastatic Pancreatic Cancer market report provides insights on the current and emerging therapies.
3. Metastatic Pancreatic Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Metastatic Pancreatic Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic Pancreatic Cancer market.

Request for sample pages

"Males show a higher proportion of incidence of Metastatic Pancreatic Cancer as compared to females in the 7MM."

Currently, pancreatic cancer treatment options include Surgery, Chemotherapy, Targeted Therapy, and Radiation Therapy, either on their own or in combination. If the cancer is in nearby organs or blood vessels (locally Metastatic) or has spread (metastasized) to other parts, surgery is not a preferred option for the treatment. Instead, in that case, treatment will focus on relieving symptoms related to jaundice, digestive problems, and pain.

Chemotherapy is a commonly preferred option for Metastatic Pancreatic Cancer. It may shrink the tumors or slow their growth and may help patients live longer. Currently, the standard chemotherapy drug for the metastatic pancreatic cancer treatment is Gemzar (Gemcitabine). In 1996, it got approved by the US Food and Drug Administration (FDA) for Pancreatic Cancer. The general side effects of treatment, including fever, infection, and elevation of liver enzymes are usually transient and easily manageable. In November 2004, the US FDA approved Erlotinib (Tarceva) manufactured by OSI Pharmaceuticals, for first-line treatment of affected patients with locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.

The current Metastatic Pancreatic Cancer market is dependent on the chemotherapeutic agents and targeted agents. Although, as there are many various side effects of currently available therapies/medication, so, there is a need for new therapies in the market with no or minimal adverse effects to provide proper Metastatic Pancreatic Cancer treatment to the affected patients. Several companies are working for the launch of new therapies to provide better corrective treatment to the patients, which can change the market outlook in the coming years.

The launch of the emerging therapies is expected to significantly impact Metastatic Pancreatic Cancer treatment scenario in the upcoming years:-
Drugs covered
1. CPI-613
2. Masitinib
3. Glufosfamide
4. TG01
And many others

The key players in Metastatic Pancreatic Cancer market are:
1. Rafael Pharm0061
2. AB Science
3. Eleison Pharmaceuticals
4. Targovax
And many others

Table of contents
1. Report Introduction
2. Executive Summary
3. SWOT Analysis
4. Metastatic Pancreatic Cancer Market Overview at a Glance
5. Metastatic Pancreatic Cancer Disease Background and Overview
6. Metastatic Pancreatic Cancer Epidemiology and Patient Population
7. Metastatic Pancreatic Cancer Country-Wise Epidemiology
7.1. United States
7.2. EU-5
7.2.1. Germany
7.2.2. France
7.2.3. Italy
7.2.4. Spain
7.2.5. United Kingdom
7.3. Japan
8. Metastatic Pancreatic Cancer Treatment & Medical Practices
9. Marketed Drugs
9.1. Erlotinib: OSI Pharmaceuticals
9.2. Gemzar: Eli Lilly
10. Metastatic Pancreatic Cancer Emerging Therapies
10.1. Key Cross Competition
10.2. CPI-613: Rafael Pharma
10.3. Masitinib: AB Science
10.4. Glufosfamide: Eleison Pharmaceuticals
10.5. TG01: Targovax
11. Attribute Analysis
12. Metastatic Pancreatic Cancer Market Size
12.1. Key Findings
12.2. Total 7MM Metastatic Pancreatic Cancer Market Analysis
13. 7MM Metastatic Pancreatic Cancer Country-Wise Market Analysis
13.1. United States
13.2. Germany
13.3. France
13.4. Italy
13.5. Spain
13.6. United Kingdom
13.7. Japan
14. Market Access and Reimbursement
15. Market Drivers
16. Market Barriers
17. Appendix
18. Metastatic Pancreatic Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight